Altogether, our data suggest a role for PSMD1, PSMD3, and STAT3 in regulating NF-κB expression and activity in CML and TKI resistance, and implicate them as potential targets for the treatment of hematologic malignancies and possibly other forms of cancer. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.